Drug-drug Interaction Study of FYU-981 and Oxaprozin

• Status: Completed
• Trial end date: 2017-12-05
• Target enrollment: 0
• Participant gender: Male

Summary

This is an open-label, 2-period add-on study to assess the drug-drug interaction between FYU-981 and oxaprozin. The purpose of this study is to investigate the pharmacokinetics of each period in a single administration of FYU-981 and concomitant administration of FYU-981 with oxaprozin at steady -state in healthy volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mochida Pharmaceutical Company, Ltd.
• Collaborator: Fuji Yakuhin Co., Ltd.
• Treatments: Dotinurad; Oxaprozin

Criteria

Inclusion Criteria:

• Adult healthy subjects

• Body mass index: >=18.5 and <25.0

Exclusion Criteria:

• Subject with any disease or any history of disease that might be unsuitable for participation in the clinical study